Reshoring Update: BMS Commits $2.3B to Houston Campus

Bristol Myers Squibb will build a new manufacturing campus at Houston's Generation Park, an investment the company put at approximately $2.3 billion in a statement announcing the project.¹ The roughly 600,000-square-foot site is expected to generate nearly 500 skilled jobs and was designed from the outset to scale beyond its initial footprint as demand rises.

BMS is funding the Houston build under a five-year, $40 billion pledge covering US research and development, technology and manufacturing.¹ The commitment lands amid a broader run of reshoring and capacity announcements from large biopharmaceutical manufacturers weighing supply chain resilience and proximity to US commercial markets against tariff policy and the cost edge of overseas production. Pharmaceutical Commerce has followed that shift through the industry's evolving domestic manufacturing push and the separate question of whether reshored capacity is landing where the supply chain needs it most.

How Does the Project Fit Into Pharma's Broader Reshoring Push?

The Houston investment is one entry in a much larger reshoring ledger.² Tariff policy and state-level incentives have pushed pharmaceutical manufacturers to pledge roughly $370 billion in domestic manufacturing and research spending over five years, with states actively bidding against one another for the projects.² Texas has widened its research and development tax credit to draw advanced manufacturing investment, and North Carolina is phasing out its corporate income tax to compete for the same dollars.³

What’s Unique About the Houston Campus?

BMS will build the site around a modular, multi-modal framework rather than a fixed layout, giving the company room to reconfigure manufacturing infrastructure as its pipeline shifts.¹ Instead of dedicating the plant to one product class, BMS designed it to run small molecule, biologic and antibody-drug conjugate production side by side, spanning drug product and finished goods manufacturing from late-stage development through commercial launch. With pipelines increasingly blending biologics, conjugates and small molecules, the ability to add capacity inside an existing campus, instead of standing up a new one, has become a bigger lever in how companies sequence capital spending and manage time to market.

Karin Shanahan, chief supply chain and operations officer at Bristol Myers Squibb, said in the press release that the facility is "designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities."¹ She added that the investment "strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands."

BMS expects construction and build-out to continue through 2030.

References

1. Bristol Myers Squibb. "Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas." Press Release. Aug. 10, 2026. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Advances-U-S--Manufacturing-Investment-with-New-2-3-Billion-Campus-in-Houston-Texas/default.aspx
2. Eschbach, A. "Reshoring Pharma: How Tariffs and Tech Are Reshaping the Next Chapter." Forbes. March 25, 2026. https://www.forbes.com/councils/forbestechcouncil/2026/03/25/reshoring-pharma-how-tariffs-and-tech-are-reshaping-the-next-chapter/
3. PwC. "North Carolina Enacts Corporate Income Tax Phase-Out." Nov. 22, 2021. https://www.pwc.com/us/en/services/tax/library/north-carolina-enacts-corporate-income-tax-phaseout.html